EGFR and non-small cell lung carcinoma: Conversely, a single-arm phase 2 trials revealed that adjuvant erlotinib in resected EGFR mutation-positive NSCLC yielded excellent 2-year disease-free survival (DFS) (94%) compared to historical genotype-matched controls18.